A review of vancomycin therapeutic drug monitoring recommendations in Scotland

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1398-1399

  Helgason, Kristjan O ^a,d   Thomson, Alison H ^b   Ferguson, Craig ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c VICTORIA HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Glycopeptides; MRSA; Treatment; Troughs

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOCARDITIS; HUMAN; INTENSIVE CARE; LETTER; MAXIMUM PLASMA CONCENTRATION; MEDICAL AUDIT; MEDICATION ERROR; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NEPHROTOXICITY; PNEUMONIA; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; GUIDELINES AS TOPIC; HUMANS; SCOTLAND; VANCOMYCIN;

EID: 44449104976     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn114     Document Type: Letter

References (9)

1. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42: S35-9.
2. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007; 45: S191-5.
3. Sakoulas G, Moellering RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42: S40-50.
4. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anethesia, American Heart Association endorsed by the Infectious Diseases Society of American. Circulation 2005; 111: 3167-84.
5. Elliott TSE, Foweraker J, Gould FK et al. Guidelines for the antibiotic treatment of endocarditis in adults: Report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-81.
6. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
7. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
8. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomised study. Antimicrob Agents Chemother 2001; 45: 2460-7.
9. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.